Skip to main content
. 2016 Feb 18;7(14):17932–17944. doi: 10.18632/oncotarget.7480

Figure 2. Hazard rate of recurrence for the overall study population (panel A) and in patients with ER and PgR staining in more than 50% of tumour cells (TP50, panel B) and other patients (noTP50, panel C).

Figure 2

Cohort A: red line; Cohort B: blue line.